^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + eftozanermin alfa (ABBV-621) (TRAIL R2 agonist, TRAIL R1 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)
Published date:
11/06/2019
Excerpt:
Antitumor activity was observed in 1 pt in the AML 621-VEN arm (with complex cytogenetics and TP53 mutation) who reached complete remission (CR).
DOI:
10.1182/blood-2019-129783
